November 02, 2025

Get In Touch

Indian-Origin Doctor Pleads Guilty To Illegally Giving Controlled Substances To Patients

US: An Indian-origin doctor pleaded guilty to illegally giving controlled substances to six patients, including one who suffered from opioid addiction and later died of a drug overdose.
Gurpreet Singh Bajwa, 49, of Fairfax, Virginia, temporarily lost his medical licence in 2012 following an investigation by the Virginia Department of Health Professions (DHP) into his prescription practices.
After his licence was reinstated, he significantly reduced the quantity of pain medications he prescribed, and switched over to stimulants, benzodiazepines, and sedatives.
Bajwa pleaded guilty to five counts of distribution of Adderall, a combination medication containing four salts of amphetamine, and one count of distribution of oxycodone and faces a maximum penalty of 20 years in prison when sentenced on May 22.
According to court documents, generally, at no point during any of his patients' visits did Bajwa or any of his staff receive, review, or request prior medical files, obtain medical histories, conduct physical examinations, discuss the case of any attention disorder or what might properly address such a condition.
Beginning in summer 2018, two undercover law-enforcement officers posed as patients and made appointments to see Bajwa.
At each visit, Bajwa prescribed the undercover officers a 30-day supply of Adderall, despite the undercover officers showing up to two weeks prior to the end of the previous 30-day period.
One of the officers told Bajwa that she was a fitness model and needed Adderall for her workouts, which is not a legitimate use for the substance.
The undercover officer also asked Bajwa to prescribe her extra pills that she could give to a "friend" and he readily agreed.
One of the patients to whom Bajwa prescribed significant quantities of prescription drugs had a history of high blood pressure, among other health conditions.
Nevertheless, Bajwa wrote her monthly prescriptions for the maximum dose of Adderall.
Read Also: Meerut Medical College: Three Doctors get life imprisonment for allegedly murdering 2nd-year MBBS student in 2004
In 2016, the Centres for Disease Control and Prevention and The Food and Drug Administration issued warnings cautioning against prescribing opioids and benzodiazepines (including Xanax) together because of the increased risk of fatal overdose.
Nevertheless, on multiple occasions, Bajwa wrote prescriptions to patients for both oxycodone—a powerful Schedule II opioid—and Xanax.
One of Bajwa's patients, named only as 'NJ' in court documents, suffered from heroin addiction.
NJ's mother told Bajwa two or three times that NJ was abusing drugs, and yet Bajwa continued to prescribe controlled substances to NJ.
In November 2017, Bajwa prescribed both oxycodone and Xanax to NJ, despite knowing of NJ's drug addiction, and despite the increased danger of combining the two medications.
In January 2018, NJ was dismissed from a rehabilitation programme after he was caught abusing drugs Bajwa prescribed him.
NJ died of a drug overdose a short time later.
Read Also: Singh Brothers held guilty of contempt by Supreme Court

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!